Research for genetic enhanced immunotherapy to the human malignant glioma.
| Project/Area Number |
13671457
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Jichi Medical School |
|---|
Principal Investigator |
NAGAI Mutsumi Jichi medical school, medical faculty, assistant, 医学部, 助手 (10265259)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OKADA Takashi Jichi medical school, medical faculty, assistant, 医学部, 助手 (00326828)
|
|---|
| Project Period (FY) |
2001 – 2002
|
| Project Status |
Completed (Fiscal Year 2002)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2002: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2001: ¥2,600,000 (Direct Cost: ¥2,600,000)
|
|---|
| Keywords | Glioma / Vaccine / MCP-1 / NK / macrophage / Gl10ma / Bim |
|---|
| Research Abstract |
We studied the effect of vaccination with MCP-1 transfectant to the malignant glioma. We obtained a human malignant glioma cell line producing human MCP-1 constitutively by transfection of MCP-1 cDNA. We then test the effect of vaccination with the MCP-1 transfectant on tumor bearing mice. In 2001, we used nude mice. Although vaccination with MCP-1 transfectant did not reduce the tumor in our study, it was associated with the infiltration of large numbers of NK cells and monocytes at the tumor site. The site of vaccination also showed large numbers of monocytes. We assumed that infiltrating monocytes at the site of vaccination could promote the infiltration of monocytes and NK cells into the tumor site without T-cell mediated transduction because the host lacked T-cell function. In 2002, we used SCID mice. In this model, we observed the treatment effect. The growth of the tumor was inhibited by the vaccine. Histological findings showed the infiltration of NK cells at the tumor site. We found the discrepancy of the treatment effect between on each mouse strain. These findings made us suggest that the B-cell function is one of the essential factors for the immune response of this vaccination strategy.
We try to manipulate SCID mice to have human immune response. As reported, we irradiated 2Gy to 6 weeks aged SCID mice. We inoculated human peripheral mononuclear cells into the mouse peritoneum. Mice were all dead at from the day 10 to 14. We are proposing to diminish the total radiation dose and try again.
|
Report
(3 results)
Research Products
(4 results)
